MW: 146,873.65 Da
No. of AA: 1276
Abs 0.1% (g/L): 1.328
pI: 5.45
NCBI ID: CAA38175.1
UniprotKB: P19321
Strains: BVD/-3
Associated Proteins:
Notes:
Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D.
Binz T, Kurazono H, Popoff MR, Eklund MW, Sakaguchi G, Kozaki S, Krieglstein K, Henschen A, Gill DM, Niemann H. (1990). Nucleic Acids Res.
DOI: PMID: 2216736
The complete amino acid sequence of the Clostridium botulinum type D neurotoxin, deduced by nucleotide sequence analysis of the encoding phage d-16 phi genome.
Sunagawa H, Ohyama T, Watanabe T, Inoue K. (1992). J. Vet. Med. Sci.
DOI: PMID: 1420572
Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC.
Zhang S, Berntsson RP, Tepp WH, Tao L, Johnson EA, Stenmark P, Dong M. (2017). Nat Commun
DOI: 10.1038/s41467-017-01534-z PMID: 29158482
Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.
Peng L, Tepp WH, Johnson EA, Dong M. (2011). PLoS Pathog.
DOI: 10.1371/journal.ppat.1002008 PMID: 21483489
Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons.
Joussain C, Le Coz O, Pichugin A, Marconi P, Lim F, Sicurella M, Salonia A, Montorsi F, Wandosell F, Foster K, Giuliano F, Epstein AL, Aranda Muñoz A. (2019). Toxins (Basel)
DOI: 10.3390/toxins11020123 PMID: 30791373
Botulinum neurotoxin serotype D - a potential treatment alternative for BoNT/A and B non-responding patients
Kutschenkoa et al. (Accepted Manuscript, In Press) (2019). Clinical Neurophysiology
DOI: 10.1016/j.clinph.2019.02.007 PMID: 30871800